BioSpace News Archive

The American Lung Association Research Institute announced it awarded $13.6 million in research grants to fund 129 innovative projects to advance today’s science to end the burden of lung disease tomorrow.

Escient Pharmaceuticals announced that the first subject has been dosed in CALM-CSU, a Phase 2 clinical proof-of-concept study of EP262 in subjects with chronic spontaneous urticaria.

Adiso Therapeutics, Inc., a clinical-stage biotechnology company committed to creating medicines that treat inflammatory diseases and improve the lives of patients and their families, announced the appointment of Robert Lisicki to the Company’s Board of Directors.

Pfizer Inc. announced that the U.S. Food and Drug Administration has approved BRAFTOVI® + MEKTOVI® for the treatment of adult patients with metastatic non-small cell lung cancer with a BRAF V600E mutation, as detected by an FDA-approved test.

Asieris Pharmaceuticals has unveiled its phase III clinical trial data for APL-1706 (Hexvix ® ), an imaging drug used for the diagnosis or surgery of bladder cancer, at the 43rd Congress of the Société Internationale d’Urologie (SIU) in 2023.

Tonix Pharmaceuticals Holding Corp. announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the ThinkEquity Conference on Thursday, October 19, 2023, at 8:00 a.m. ET, and host investor meetings.

Entrada Therapeutics, Inc. today announced it will participate in the following two investor conferences.

InspireMD, Inc., developer of the CGuard™ Embolic Prevention Stent System for the prevention of stroke, announced its support for the Centers for Medicare and Medicaid Services final National Coverage Determination which expands coverage of carotid artery stenting and transcarotid artery revascularization to include both asymptomatic and standard risk patients.

Sharecare (Nasdaq: SHCR ), the digital health company that helps people manage all their health in one place, today announced that it will report third quarter fiscal 2023 financial results on Thursday, November 9, 2023, before the market opens.

South Rampart Pharma, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company for SRP-001 for the treatment of acute pain.